CARR enters this week having delivered one of its best five-day runs of the year — a 7.3% gain to $71.24 — while short sellers quietly pared back exposure and options traders hedged defensively into the move.
The sharpest data point this week is the speed of the short covering. Short interest fell 16% in a single day on June 9, dropping to roughly 1.9% of the free float — down from about 2.3% a month ago. That level was already modest, but the pace of the unwind stands out. The 30-day decline in shares short now runs at 16.5%, consistent with a market that turned more positive on CARR after the stock's post-earnings rip. April 30 results delivered a 9.5% single-day gain and held most of that ground through the following week, and the short book has been shrinking ever since. Borrow costs are negligible at 0.44% annualised, and availability is extraordinarily loose — shares outstanding available to lend run at more than 3,200% of current short interest, meaning there is virtually no friction for anyone who still wants to add a short position.
Options positioning tells the more interesting story. Put/call ratio has climbed to 1.31, nearly two standard deviations above its 20-day average of 1.21 — the most defensively skewed reading in roughly six weeks. That is a notable divergence from the price action: the stock just rallied hard, yet the options market is hedging more, not less. One plausible read is that some holders accumulated into the rally and are now protecting gains through puts. The PCR's 52-week range runs from 0.75 to 2.13, so the current reading is elevated but not extreme.
The Street is broadly constructive, though with meaningful gaps in ambition. Bernstein initiated this morning at Market Perform with a $75 target — a vote of confidence in the business but a signal that the analyst community's newest voice sees limited near-term upside from current levels. Morgan Stanley, maintaining Equal-Weight, raised its target to $60 in late May, still well below the stock's current price; that disconnect is worth flagging. JPMorgan moved its Neutral target from $63 to $67 in mid-May. The more bullish cluster — Citi at $79, RBC at $81, Barclays at $79, Evercore at $85 — all lifted targets after the Q1 print and maintain positive ratings. The consensus mean target sits near $76, roughly 7% above the current price. The bull case centres on HVAC demand resilience, the Viessmann Climate Solutions integration, and exposure to datacentre cooling and electrification; the bear case points to macro headwinds, residential market softness, and a pending HVAC price-fixing lawsuit. The valuation has moved with the stock: the trailing P/E now runs near 24x and EV/EBITDA around 14.9x, both up roughly 10% over the past 30 days as the stock re-rated post-earnings.
One ownership development warrants attention. Viessmann Generations Group — the family entity that received CARR shares as consideration for the Viessmann Climate Solutions acquisition — trimmed its holding by approximately 12.1 million shares on May 20, a $750 million sale representing 4.6% of the company. The move reduced Viessmann's stake to around 4.6% of shares outstanding, and it is now visible in the institutional register as a declining holder. Capital Research and Management remains by far the dominant external shareholder, owning 17.8% after adding 24 million shares in the most recent reporting period — a meaningful accumulation that somewhat offsets the Viessmann selling pressure.
The ORTEX short score has been drifting lower all month, falling from 34.2 on May 29 to 32.0 today — a direction consistent with a stock where short interest is unwinding and the borrow market is loose. Peers LII and TT both gained around 2.5% on the week, and JCI added 4%, confirming the HVAC and building products sector broadly participated in this week's rally rather than CARR moving in isolation. The outlier is MOD, down 9.4% on the week — a reminder that not every corner of the building products universe is seeing the same tailwind.
With no next earnings date yet announced, the near-term focus shifts to whether the Street's laggard price targets — particularly Morgan Stanley's $60 — get revised up to align with the post-earnings reality, and whether the defensive options positioning resolves as gains are either locked in or the stock consolidates.
See the live data behind this article on ORTEX.
Open CARR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
